Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp205 | Pituitary Clinical | ECE2018

Predictors of response to long-acting pasireotide in patients with Cushing’s disease during a Phase III study

Witek Przemyslaw , Biller Beverly M K , Lacroix Andre , Feelders Richard , Li Yiming , Geer Eliza B , Brue Thierry , Ravichandran Shoba , Tauchmanova Libuse , Roughton Michael , Petersenn Stephan

Introduction: Long-acting pasireotide reduced urinary free cortisol (UFC) in most patients with CushingÂ’s disease (CD) during a large Phase III study (Lacroix et al. Lancet Diabetes Endocrinol 2018). The analyses presented here explored the impact of baseline characteristics on response to long-acting pasireotide.Methods: 150 patients with persistent, recurrent or de novo CD and mean UFC (mUFC; from three 24-hour samples collected ...